Last updated on March 2018

A Study Evaluating the Efficacy and Safety of the LentiGlobin BB305 Drug Product in Subjects With Transfusion-Dependent -Thalassemia Who do Not Have a 0/ 0 Genotype


Brief description of study

This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 23 subjects 50 years of age with transfusion-dependent -thalassemia (TDT), also known as -thalassemia major, who do not have a 0 mutation at both alleles of the hemoglobin (HBB) gene. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.

Clinical Study Identifier: NCT02906202

Contact Investigators or Research Sites near you

Start Over

bluebird bio

Oakland, CA United States
  Connect »

bluebird bio

Chicago, IL United States
  Connect »

bluebird bio

Philadelphia, PA United States
  Connect »

bluebird bio

Marseille, France
  Connect »

bluebird bio

Hannover, Germany
  Connect »

bluebird bio

Thessaloniki, Greece
  Connect »

bluebird bio

Bangkok, Thailand
  Connect »

bluebird bio

London, United Kingdom
  Connect »